
David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.

David Cherney, MD, PhD, is Professor of Medicine and Gabor Zellerman Chair of Nephrology Research, University of Toronto. He is a Clinician Scientist in the Division of Nephrology at the University Health Network and Mount Sinai Hospitals and Director of the Renal Physiology Laboratory at UHN.

David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.